Prevention Of Stroke In Nonvalvular Atrial Fibrillation
Key Points
Key Points
- The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
- The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
- For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
- The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.
Diagnosis
...agnosis...
...Stroke Risk in Patients With Nonva...
...e 1. Patterns of Atrial Fibrillation
Treatment
...atment...
...arin (A)300167
...abigatran (B)300167
...ixaban (B)30...
...roxaban (B)300...
...e safety and efficacy of combining dabi...
... Clopidogrel & Warfarin...
...justed-dose warfarin (target INR – 2.0...
...erapy with aspirin is recommended for low-...
...patients with AF deemed unsuitable for anticoagu...
...r patients with ischemic stroke or TI...
...ble to take oral anticoagulants, a...
...on of clopidogrel plus aspirin carries a r...
Dabigat...
...bigatran is useful as an alternativ...
...mg twice daily is an efficacious...
...basis of pharmacokinetic data, the...
...se there are no data to support th...
...ixaban
...mg twice daily is an efficacious alternative to as...
Although its safety and efficacy have not been est...
...5 mg twice daily is a relatively safe and effic...
...ugh its safety and efficacy have not b...
...ixaban should NOT be used if the CrCI is...
...aroxaban...
...tients with nonvalvular AF who are a...
...with renal impairment and nonvalvular AF who are...
...ould NOT be used if the CrCI is...
...Recommended for Stroke PreventionaHaving tro...
...2. Prevention of Stroke in Nonvalvular Atrial Fi...